Guidance
Evidence-based recommendations on The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites.
In September 2019, we updated this guidance to reflect 2019 costs. Details of the modifications are explained in the review decision. The update also includes revised cost-saving estimates. New evidence and updated costs identified during the guidance review are denoted as [2019].
Implementation
NICE has developed tools, in association with relevant stakeholders, to help organisations put this guidance into practice.
Is this guidance up to date?
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.
Guidance development process
How we develop NICE medical technologies guidance
NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
This guidance was previously called The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites.